In the predominant sequence-to-function paradigm, 3-D structure is an obligatory prerequisite for protein function. Even though over 100 counter examples can be found in literature, generalization of the functions associated with non-folded (disordered) protein has been mostly ignored. Applying our proprietary bioinformatics software PONDRs on oncogenes, a large fraction of cancer-associated proteins was found to contain large intrinsically disordered regions crucial to function. Thus, a cancer-specific resource database, Cancer DisProtTM and its companion protocol manual will be developed to incorporate functional disordered data for oncogenes. Using PONDRs, disorder/order predictions will be correlated with functions of a representative set of cancer-associated proteins. Data mining these correlations should reveal relationships between disorder/order state and various protein functions, demonstrating the utility of this approach. Ultimately, Cancer DisProt database will be a compendium of hundreds of cancer-associated proteins with experimentally determined regions of disorder correlated with functions. Cancer DisProt will be a useful bioinformatics tool for functional annotation of entire genomes. The database, augmented with methods for studying counter example proteins, will provide the basis for design of novel approaches to the development of cancer treatments and/or drug discovery.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA097629-01
Application #
6548979
Study Section
Special Emphasis Panel (ZRG1-SSS-H (01))
Program Officer
Heath, Anne K
Project Start
2002-09-19
Project End
2003-08-31
Budget Start
2002-09-19
Budget End
2003-08-31
Support Year
1
Fiscal Year
2002
Total Cost
$100,000
Indirect Cost
Name
Molecular Kinetics, Inc.
Department
Type
DUNS #
183789163
City
Indianapolis
State
IN
Country
United States
Zip Code
46268
Cheng, Yugong; LeGall, Tanguy; Oldfield, Christopher J et al. (2006) Rational drug design via intrinsically disordered protein. Trends Biotechnol 24:435-42